// App-Quantinova.ai

SAT0270 (2018) : Low incidence of both new-onset and flares of uveitis in secukinumab-treated patients with ankylosing spondylitis: clinical trial and post-marketing safety analysis

Researchers

Presenter

  • A. Deodhar

Principal Investigators

  • C. Miceli-Richard

  • X. Baraliakos

  • H. Marzo-Ortega

  • D.D. Gladman

  • R. Martin

  • J. Safi

  • B. Porter

  • A. Shete

Medical Centers

  • Oregon Health and Science University, Portland, OR

  • Hopital Cochin, Paris, France

  • Rheumazentrum Ruhrgebiet, Herne, Germany

  • IHR LBRC, LTHT and LIRMM, University of Leeds, Leeds, UK

  • Toronto Western Hospital, Toronto, ON, Canada

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Novartis AG, Basel, Switzerland

Locations

  • United States

  • France

  • Germany

  • United Kingdom

  • Canada

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Ophthalmology (OP)

  • Musculoskeletal

Disease

  • Ankylosing spondylitis

  • Uveitis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01649375

  • NCT02008916]

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved